Esophagitis in children: an update on current pharmacotherapy

Bibliography

• Thompson M. Pediatric esophagus come of age. J Pediatr Gastroenterol Nutr 2002;34:S40-5
   Web of Science ®Google Scholar
• Thompson M. Esophagitis. In: Kleinman RE, Goulet O, Meili-Vergani G, et al. editors. Pediatric Gastrointestinal disease: physiology, diagnosis, management. 5th edition. ( Volume 1). BC Decker; Hamilton, Ontario: 2008. p. 87
   Google Scholar
• Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49:498-547
   PubMed Web of Science ®Google Scholar
• Sherman PM, Hassall E, Fagundes-Neto U. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009;104(5):1278-95
   PubMed Web of Science ®Google Scholar
• Genta RM, Spechler SJ, Kielhorn AF. The Los Angeles and savary-miller systems for grading esophagitis: utilization and correlation with histology. Dis Esophagus 2011;24(1):10-17
   PubMed Web of Science ®Google Scholar
• Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy. Arch Pediatr Adolesc Med 1997;151:569-72
   PubMed Web of Science ®Google Scholar
• Hegar B, Vandenplas Y. Gastroesophageal reflux: natural evolution, diagnostic approach and treatment. Turk J Pediatr 2013;55:1-7
   PubMed Web of Science ®Google Scholar
• Hyams JS, Ricci A Jr, Leichtner AM. Clinical and laboratory correlates of esophagitis in young children. J Pediatr Gastroenterol Nutr 1988;7(1):52-6
   PubMed Web of Science ®Google Scholar
• Salvatore S, Hauser B, Devreker T, et al. Esophageal impedance and esophagitis in children: any correlation? J Pediatr Gastroenterol Nutr 2009;49:566-70
   PubMed Web of Science ®Google Scholar
• Vandenplas Y, Badriul H, Verghote M, et al. Oesophageal pH monitoring and reflux oesophagitis in irritable infants. Eur J Pediatr 2004;163:300-4
   PubMed Web of Science ®Google Scholar
• Heine RG, Cameron DJ, Chow CW, et al. A poor diagnostic agreement between esophageal pH monitoring and histopathologic findings for esophagitis in distressed infants. J Pediatr 2002;140:14-19
   PubMed Web of Science ®Google Scholar
• Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007;45:421-7
   PubMed Web of Science ®Google Scholar
• Scherer LD, Zikmund-Fisher BJ, Fagerlin A, Tarini BA. Influence of "GERD" label on parents' decision to medicate infants. Pediatrics 2013;131(5):839-45
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505
   PubMed Web of Science ®Google Scholar
• Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Pediatr Drugs 2013;15:119-31
   PubMed Web of Science ®Google Scholar
• Omari T, Lundborg P, Sandström M, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr 2009;155:222-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Kukulka M, Witt G, et al. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Pediatr Drugs 2008;10:265-74
   PubMedGoogle Scholar
• Omari TI, Davidson GP, Bondarov P, et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:530-7
   PubMed Web of Science ®Google Scholar
• Sandström M, Davidson G, Tolia V, et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther 2012;34(8):1828-38
   PubMed Web of Science ®Google Scholar
• Orenstein S, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514-20
   PubMed Web of Science ®Google Scholar
• Winter HW, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of GERD in infants ages 1–11 months. J Pediatr Gastroenterol Nutr 2012;55:14-20
   PubMed Web of Science ®Google Scholar
• Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1–11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010;50(6):609-18
   PubMed Web of Science ®Google Scholar
• van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011;127(5):925-35
   PubMed Web of Science ®Google Scholar
• Chen IL, Gao WY, Johnson AP, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012;54:8-14
   PubMed Web of Science ®Google Scholar
• Borowitz SM. Ulcerative esophagitis. Rare source of upper gastrointestinal bleeding in a neonate. Use of fiberoptic endoscopy for diagnosis. Clin Pediatr 1989;28:89-91
   PubMed Web of Science ®Google Scholar
• Wongsawasdi L, Ukarapol N, Chotinaruemol S. Severe upper gastrointestinal hemorrhage in the newborn. J Med Assoc Thai 2002;85(1):114-19
   PubMedGoogle Scholar
• Gilger MA, El-Serag HB, Gold BD, et al. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr 2008;47:141-6
   PubMed Web of Science ®Google Scholar
• Tolia V, Gilger MA, Barker PN. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. J Pediatr Gastroenterol Nutr 2010;51(5):593-8
   PubMed Web of Science ®Google Scholar
• Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007;150(3):262-7
   PubMed Web of Science ®Google Scholar
• Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008;53(2):385-93
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Bailey NR, Gilger M, Rabeneck L. Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol 2002;97:1635-9
   PubMed Web of Science ®Google Scholar
• Tolia V, Youssef NN, Gilger MA, et al. Esomeprazole for the treatment of erosive esophagitis in children: an international multicenter randomized parallel-group double-blind (for dose) study. BMC Pediatr 2010;10:41-9
   PubMedGoogle Scholar
• Drugs@FDA. Available from: http://www.accessdata.fda.gov [Accessed 1 July 2013]
   Google Scholar
• Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000;137:800-7
   PubMed Web of Science ®Google Scholar
• Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35(Suppl 4):S308-18
   PubMedGoogle Scholar
• Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36:261-5
   PubMed Web of Science ®Google Scholar
• De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32
   PubMed Web of Science ®Google Scholar
• Faure C, Michaud L, Khan Shaghaghi E, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402
   PubMed Web of Science ®Google Scholar
• Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6
   PubMedGoogle Scholar
• Tolia V, Bishop PR, Marc Tsou V, et al. Members of the 322 Study Group. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006;42:384-91
   PubMed Web of Science ®Google Scholar
• Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54
   PubMed Web of Science ®Google Scholar
• Pfefferkorn MD, Croffie JM, Gupta SK, et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Pediatr Gastroenterol Nutr 2006;42:160-5
   PubMed Web of Science ®Google Scholar
• Kirsch R, Bokhary R, Marcon MA, Cutz E. Activated mucosal mast cells differentiate eosinophilic (Allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;44:20-6
   PubMed Web of Science ®Google Scholar
• Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63
   PubMed Web of Science ®Google Scholar
• Mulder DJ, Hurlbut DJ, Noble AJ, Justinich CJ. Clinical features distinguish eosinophilic and reflux-induced esophagitis. J Pediatr Gastroenterol Nutr 2013;56:263-70
   PubMed Web of Science ®Google Scholar
• Markowitz JE, Spergel JM, Ruchelli E, et al. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003;98:777-82
   PubMed Web of Science ®Google Scholar
• Kagalwalla AF, Sentongo TA, Ritz S. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1097-102
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998;26:380-5
   PubMed Web of Science ®Google Scholar
• Teitelbaum J, Fox V, Twarog F, et al. Eosinohphilic esophagitis in children: immunopathological analysis and response to fluticasone propionate Gastroenterology 2002;122:1216-25
   Google Scholar
• Noel RJ, Putnam PE, Collin MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastreoenterol Hepatol 2004;2:568-75
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165-73
   PubMed Web of Science ®Google Scholar
• Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139(2):418-29
   PubMed Web of Science ®Google Scholar
• Otani IM, Anilkumar AA, Newbury RO, et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 2013;131(6):1576-82
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129(2):456-63
   PubMed Web of Science ®Google Scholar
• Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141(5):1593-604
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128(1):3-20
   PubMed Web of Science ®Google Scholar
• Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009;104:716-21
   PubMed Web of Science ®Google Scholar
• Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease. There and back again. Clin Gastroenterol Hepatol 2011;9(2):99-101
   PubMed Web of Science ®Google Scholar
• Rosen R, Furuta G, Fritz J, et al. Role of acid and nonacid reflux in children with eosinophilic esophagitis compared with patients with gastroesophageal reflux and control patients. J Pediatr Gastroenterol Nutr 2008;46:520-3
   PubMed Web of Science ®Google Scholar
• Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus: peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666-70
   PubMed Web of Science ®Google Scholar
• Sayej W, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;49:393-9
   PubMed Web of Science ®Google Scholar
• Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012;57(5):1413-19
   PubMed Web of Science ®Google Scholar
• Levine J, Lai J, Edelman M, Schuval SJ. Conservative long-term treatment of children with eosinophilic esophagitis. Ann Allergy Asthma Immunol 2012;108(5):363-6
   PubMed Web of Science ®Google Scholar
• Schroeder S, Capocelli KE, Masterson JC, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013;56:166-72
   PubMed Web of Science ®Google Scholar
• Rea F, Caldaro T, Tambucci R. Eosinophilic esophagitis: is it also a surgical disease? J Pediatr Surg 2013;48(2):304-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Cheng E, Huo X, et al. In esophageal squamous epithelial cell lines from patients with eosinophilic esophagitis (EoE), omeprazole blocks the stimulated secretion of eotaxin-3: a potential anti-inflammatory effect of omeprazole in EoE that is independent of acid inhibition. Gastroenterology 2010;138:S-122
   Web of Science ®Google Scholar
• Cheng E. Proton pump inhibitors for eosinophilic oesophagitis. Curr Opin Gastroenterol 2013;29(4):416-20
   PubMed Web of Science ®Google Scholar
• Pohl JF. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr 2012;24(5):627-31
   PubMed Web of Science ®Google Scholar
• Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-8
   PubMed Web of Science ®Google Scholar
• Canani RB, Pia Cirillo P, Paola Roggero P, et al. The Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117(5):817-20
   PubMed Web of Science ®Google Scholar
• Gabello M, Valenzano MC, Zurbach EP, Mullin JM. Omeprazole induces gastric transmucosal permeability to the peptide bradykinin. World J Gastroenterol 2010;16(9):1097-103
   PubMed Web of Science ®Google Scholar
• Merwat SN, Spechler SJ. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol 2009;104(8):1897-902
   PubMed Web of Science ®Google Scholar
• Drut R, Altamirano E, Cueto Rua E. Omeprazole-associated changes in the gastric mucosa of children. J Clin Pathol 2008;61:754-6
   PubMed Web of Science ®Google Scholar
• Hassall E, Owen D, Kerr W, et al. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term. Gastroenterology 2008;134:A174; A110
   Web of Science ®Google Scholar
• Lodrupi AB, Reimer C, Byzter P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 2013;48:515-22
   PubMed Web of Science ®Google Scholar
• Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;24:945-54
   PubMed Web of Science ®Google Scholar
• Jones R, Armstrong D, Malfertheiner P, Ducrotte P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr Med Res Opin 2006;22:657-62
   PubMed Web of Science ®Google Scholar
• Zerbib F, Duriez A, Roman S, et al. Determinants of gastrooesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156-60
   PubMed Web of Science ®Google Scholar
• Cossentino MJ, Mann K, Armbruster SP, et al. Randomised clinical trial: the effect of baclofen in patients with gastrooesophageal reflux - a randomized prospective study. Aliment Pharmacol Ther 2012;35:1036-44
   PubMed Web of Science ®Google Scholar
• Vakil NB, Huff FJ, Cundy KC. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease - insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther 2013;38(2):107-17
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Denison H, Björck K, et al. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut 2012;51:1601-9
   Google Scholar
• Kawai M, Kawahara H, Hirayama S, et al. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004;38(3):317-23
   PubMed Web of Science ®Google Scholar
• Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006;149(4):468-74
   PubMed Web of Science ®Google Scholar
• Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr 2012;54:41-7
   PubMed Web of Science ®Google Scholar
• van der Pol RJ, Smits MJ, Venmans L, et al. Diagnostic accuracy of tests in pediatric gastroesophageal reflux disease. J Pediatr 2013;162:983-7
   PubMed Web of Science ®Google Scholar
• Salvatore S, Hauser B, Vandemaele K, et al. Gastroesophageal reflux disease in infants: how much is predictable with questionnaires, pH-metry, endoscopy and histology? J Pediatr Gastroenterol Nutr 2005;40:210-15
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Mittal SK, Kalra KK, et al. Infant gastroesophageal reflux disease score: reproducibility and validity in a developing country. Trop Gastroenterol 2004;25:96-8
   PubMedGoogle Scholar
• Septer S, Cuffari C, Attard TM. Esophageal polyps in pediatric patients undergoing routine diagnostic upper gastrointestinal endoscopy: a multicenter study. Dis Esophagus 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Ravelli AM, Villanacci V, Ruzzenenti N, et al. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 2006;42:510-15
   PubMed Web of Science ®Google Scholar
• Sherrill JD, Gao PS, Stucke EM, et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 2010;126:160-5
   PubMed Web of Science ®Google Scholar
• Kagalwalla AF, Akhtar N, Woodruff SA, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with Treatment. J Allergy Clin Immunol 2012;129:1387-96
   PubMed Web of Science ®Google Scholar